Long term survival results in advanced prostate cancer treated with combined androgen blockade.
- Author:
Shi-ge ZHANG
1
;
Yi-hua WANG
;
Yi DING
;
Ye WU
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Androgen Antagonists; therapeutic use; Combined Modality Therapy; Flutamide; therapeutic use; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Neoplasms; drug therapy; mortality; surgery; Survival Rate
- From: National Journal of Andrology 2005;11(10):770-774
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo understand long-term survival rate after combined androgen blockade (CAB) in patients with advanced prostate cancer.
METHODSA selected population of 59 patients with advanced prostate cancer were treated with CAB. 28.81% (17/59) of patients had clinical locally advanced disease (stage T3-4N0M0), and 45.76% (27/59) of patients had metastatic disease (stage TxNxM+). Overall, patients were followed for a median of 62 (range 6-136) months.
RESULTSOf the 59 patients with advanced prostate cancer, 3-year, 5-year and 7-year overall survival rates were 79.36%, 61.46% and 49.15%, respectively. The 5-year survival rate were 80.77% and 32.65% for clinical locally advanced disease and metastatic disease. Specifically, men with poorly differentiated prostate cancer had a 5-year survival of only 30% when compared with men with well-differentiated prostate disease who had a 5-year survival of 86.21%.
CONCLUSIONBased on these findings, men with poorly differentiated cancer, stage T3c-4NxMx or TxNxM+ and PSA level above 30 microg/L had a high probability of dying from their advanced prostate cancer.
